Polycyclic aromatic hydrocarbon-DNA adduct formation in prostate carcinogenesis

Cancer Letters

Volumn 239, Issue 2, 2006, Pages 157-167

  Rybicki, Benjamin A ^a   Nock, Nora L ^b   Savera, Adnan T ^a   Tang, Deliang ^c   Rundle, Andrew ^c  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Mailman School of Public Health   (United States)

Author keywords

Benzo(a)pyrene; DNA damage; DNA repair; Immunohistochemistry

Indexed keywords

BIOLOGICAL MARKER; CARCINOGEN; DNA; POLYCYCLIC AROMATIC HYDROCARBON;

CARBON METABOLISM; CARCINOGENESIS; DNA ADDUCT; DNA DAMAGE; DNA REPAIR; HUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; SHORT SURVEY; VALIDATION STUDY;

EID: 33745673147     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.07.029     Document Type: Review

References (81)

1. S.K. Yang, B.D. Silverman (eds.). Polycyclic Aromatic Hydrocarbon Carcinogenesis: Structure-activity Relationships, CRC Press, Boca Raton, FL, 1988.
2. Tolbert P.E. Oils and cancer. Cancer Causes Control 8 (1997) 386-405
3. Phillips D.H. Polycyclic aromatic hydrocarbons in the diet. Mutat. Res. 443 (1999) 139-147
4. Shimada T., Yamazaki H., Foroozesh M., Hopkins N.E., Alworth W.L., and Guengerich F.P. Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1. Chem. Res. Toxicol. 11 (1998) 1048-1056
5. Scherer G., Frank S., Riedel K., Meger-Kossien I., and Renner T. Biomonitoring of exposure to polycyclic aromatic hydrocarbons of nonoccupationally exposed persons. Cancer Epidemiol. Biomarkers Prev. 9 (2000) 373-380
6. Schoket B. Monitoring occupational exposure to carcinogens. IARC Sci. Publ. (1993) 341-347
7. Potter M. Percivall Pott's contribution to cancer research. Natl Cancer Inst. Monogr. 10 (1963) 1-13
8. Chen T.T., and Heidelberger C. Quantitative studies on the malignant transformation of mouse prostate cells by carcinogenic hydrocarbons in vitro. Int. J. Cancer 4 (1969) 166-178
9. Grover P.L., Sims P., Huberman E., Marquardt H., Kuroki T., and Heidelberger C. In vitro transformation of rodent cells by K-region derivatives of polycyclic hydrocarbons. Proc. Natl Acad. Sci. USA 68 (1971) 1098-1101
10. Guttenplan J.B., Chen M., Kosinska W., Thompson S., Zhao Z., and Cohen L.A. Effects of a lycopene-rich diet on spontaneous and benzo[a]pyrene-induced mutagenesis in prostate, colon and lungs of the lacZ mouse. Cancer Lett. 164 (2001) 1-6
11. Ovrebo S., Haugen A., Hemminki K., Szyfter K., Drablos P.A., and Skogland M. Studies of biomarkers in aluminum workers occupationally exposed to polycyclic aromatic hydrocarbons. Cancer Detect. Prev. 19 (1995) 258-267
12. Pavanello S., Siwinska E., Mielzynska D., and Clonfero E. GSTM1 null genotype as a risk factor for anti-BPDE-DNA adduct formation in mononuclear white blood cells of coke-oven workers. Mutat. Res. 558 (2004) 53-62
13. Parent M.E., and Siemiatycki J. Occupation and prostate cancer. Epidemiol. Rev. 23 (2001) 138-143
14. Brown D.A., and Delzell E. Motor vehicle manufacturing and prostate cancer. Am. J. Ind. Med. 38 (2000) 59-70
15. Nadon L., Siemiatycki J., Dewar R., Krewski D., and Gerin M. Cancer risk due to occupational exposure to polycyclic aromatic hydrocarbons. Am. J. Ind. Med. 28 (1995) 303-324
16. Aronson K.J., Siemiatycki J., Dewar R., and Gerin M. Occupational risk factors for prostate cancer: results from a case- control study in Montreal, Quebec, Canada. Am. J. Epidemiol. 143 (1996) 363-373
17. van der Gulden J.W., Kolk J.J., and Verbeek A.L. Work environment and prostate cancer risk. Prostate 27 (1995) 250-257
18. Seidler A., Heiskel H., Bickeboller R., and Elsner G. Association between diesel exposure at work and prostate cancer. Scand. J. Work Environ. Health 24 (1998) 486-494
19. Siemiatycki J., Wacholder S., Richardson L., Dewar R., and Gerin M. Discovering carcinogens in the occupational environment. Methods of data collection and analysis of a large case-referent monitoring system. Scand. J. Work Environ. Health 13 (1987) 486-492
20. Elghany N.A., Schumacher M.C., Slattery M.L., West D.W., and Lee J.S. Occupation, cadmium exposure, and prostate cancer. Epidemiology 1 (1990) 107-115
21. Hansen E.S. A follow-up study on the mortality of truck drivers. Am. J. Ind. Med. 23 (1993) 811-821
22. Boffetta P., Stellman S.D., and Garfinkel L. Diesel exhaust exposure and mortality among males in the American Cancer Society prospective study. Am. J. Ind. Med. 14 (1988) 403-415
23. Evanoff B.A., Gustavsson P., and Hogstedt C. Mortality and incidence of cancer in a cohort of Swedish chimney sweeps: an extended follow up study. Br. J. Ind. Med. 50 (1993) 450-459
24. Kolonel L.N. Fat, meat, and prostate cancer. Epidemiol. Rev. 23 (2001) 72-81
25. Hickey K., Do K.A., and Green A. Smoking and prostate cancer. Epidemiol. Rev. 23 (2001) 115-125
26. Autrup J.L., Thomassen L.H., Olsen J.H., Wolf H., and Autrup H. Glutathione S-transferases as risk factors in prostate cancer. Eur. J. Cancer Prev. 8 (1999) 525-532
27. Mao G.E., Morris G., Lu Q.Y., Cao W., Reuter V.E., Cordon-Cardo C., et al. Glutathione S-transferase P1 Ile105Val polymorphism, cigarette smoking and prostate cancer. Cancer Detect. Prev. 28 (2004) 368-374
28. Miller E.C., and Miller J.A. Mechanisms of chemical carcinogenesis. Cancer 47 (1981) 1055-1064
29. I.G. Sipes, A.J. Gandolfi, Biotransformation of toxicants in: M. Amdur, J. Doull, C. Klaassen (Eds.), Casarett and Doull's Toxicology: The Basic Science of Poisons, McGraw-Hill, New York, 1991, pp. 88-126.
30. K.M. Sterling, Jr., K.R. Cutroneo. Constitutive and inducible expression of cytochromes P4501A (CYP1A1 and CYP1A2) in normal prostate and prostate cancer cells, J. Cell. Biochem. 91 (2004) 423-429.
31. Widschwendter M., Siegmund K.D., Muller H.M., Fiegl H., Marth C., Muller-Holzner E., et al. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res. 64 (2004) 3807-3813
32. Williams J.A., Martin F.L., Muir G.H., Hewer A., Grover P.L., and Phillips D.H. Metabolic activation of carcinogens and expression of various cytochromes P450 in human prostate tissue. Carcinogenesis 21 (2000) 1683-1689
33. Ragavan N., Hewitt R., Cooper L.J., Ashton K.M., Hindley A.C., Nicholson C.M., et al. CYP1B1 expression in prostate is higher in the peripheral than in the transition zone. Cancer Lett. 215 (2004) 69-78
34. Carnell D.M., Smith R.E., Daley F.M., Barber P.R., Hoskin P.J., Wilson G.D., et al. Target validation of cytochrome P450 CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue. Int. J. Radiat. Oncol. Biol. Phys. 58 (2004) 500-509
35. Shimada T., Hayes C.L., Yamazaki H., Amin S., Hecht S.S., Guengerich F.P., and Sutter T.R. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res. 56 (1996) 2979-2984
36. Sims P., Grover P.L., Swaisland A., Pal K., and Hewer A. Metabolic activation of benzo(a)pyrene proceeds by a diol-epoxide. Nature 252 (1974) 326-328
37. Yang S.K., McCourt D.W., Roller P.P., and Gelboin H.V. Enzymatic conversion of benzo(a)pyrene leading predominantly to the diol-epoxide r-7,t-8-dihydroxy-t-9,10-oxy-7,8,9,10-tetrahydrobenzo(a)pyrene through a single enantiomer of r-7, t-8-dihydroxy-7,8-dihydrobenzo(a)pyrene. Proc. Natl Acad. Sci. USA 73 (1976) 2594-2598
38. Wood A.W., Chang R.L., Levin W., Thakker D.R., Yagi H., Sayer J.M., et al. Mutagenicity of the enantiomers of the diastereomeric bay-region benzo(c)phenanthrene 3,4-diol-1,2-epoxides in bacterial and mammalian cells. Cancer Res. 44 (1984) 2320-2324
39. Levin W., Chang R.L., Wood A.W., Thakker D.R., Yagi H., Jerina D.M., and Conney A.H. Tumorigenicity of optical isomers of the diastereomeric bay-region 3,4-diol-1,2-epoxides of benzo(c)phenanthrene in murine tumor models. Cancer Res. 46 (1986) 2257-2261
40. Burczynski M.E., and Penning T.M. Genotoxic polycyclic aromatic hydrocarbon ortho-quinones generated by aldo-keto reductases induce CYP1A1 via nuclear translocation of the aryl hydrocarbon receptor. Cancer Res. 60 (2000) 908-915
41. Penning T.M., Burczynski M.E., Jez J.M., Hung C.F., Lin H.K., Ma H., et al. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem. J. 351 (2000) 67-77
42. Flowers L., Bleczinski W.F., Burczynski M.E., Harvey R.G., and Penning T.M. Disposition and biological activity of benzo[a]pyrene-7,8-dione. A genotoxic metabolite generated by dihydrodiol dehydrogenase. Biochemistry 35 (1996) 13664-13672
43. Hayes J.D., and Pulford D.J. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit. Rev. Biochem. Mol. Biol. 30 (1995) 445-600
44. Mannervik B., and Widersten M. Human glutathione transferases: classification, tissue distribution, structure and functional properties. In: Pacifici G.M., and Fracchia G.N. (Eds). Advances in Drug Metabolism in Man (1995), European Commission, Brussels/Luxembourg 408-459
45. Sundberg K., Widersten M., Seidel A., Mannervik B., and Jernstrom B. Glutathione conjugation of bay- and fjord-region diol epoxides of polycyclic aromatic hydrocarbons by glutathione transferases M1-1 and P1-1. Chem. Res. Toxicol. 10 (1997) 1221-1227
46. Jeronimo C., Usadel H., Henrique R., Oliveira J., Lopes C., Nelson W.G., and Sidransky D. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J. Natl Cancer Inst. 93 (2001) 1747-1752
47. Lodygin D., Epanchintsev A., Menssen A., Diebold J., and Hermeking H. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res. 65 (2005) 4218-4227
48. Weinstein I.B., Jeffrey A.M., Jennette K.W., Blobstein S.H., Harvey R.G., Harris C., et al. Benzo(a)pyrene diol epoxides as intermediates in nucleic acid binding in vitro and in vivo. Science 193 (1976) 592-595
49. Cavalieri E.L., Rogan E.G., Devanesan P.D., Cremonesi P., Cerny R.L., Gross M.L., and Bodell W.J. Binding of benzo[a]pyrene to DNA by cytochrome P-450 catalyzed one-electron oxidation in rat liver microsomes and nuclei. Biochemistry 29 (1990) 4820-4827
50. Melendez-Colon V.J., Luch A., Seidel A., and Baird W.M. Cancer initiation by polycyclic aromatic hydrocarbons results from formation of stable DNA adducts rather than apurinic sites. Carcinogenesis 20 (1999) 1885-1891
51. Cavalieri E.L., Rogan E.G., and Chakravarti D. Initiation of cancer and other diseases by catechol ortho-quinones: a unifying mechanism. Cell Mol. Life Sci. 59 (2002) 665-681
52. Poirier M.C., and Weston A. Human DNA adduct measurements: state of the art. Environ. Health Perspect. 104 (1996) 883-893
53. Gupta R.C., Reddy M.V., and Randerath K. 32P-postlabeling analysis of non-radioactive aromatic carcinogen-DNA adducts. Carcinogenesis 3 (1982) 1081-1092
54. Bolton J.L., Trush M.A., Penning T.M., Dryhurst G., and Monks T.J. Role of quinones in toxicology. Chem. Res. Toxicol. 13 (2000) 135-160
55. Denissenko M., Pao A., Tang M., and Pfiefer G. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science 274 (1996) 430-432
56. Gunther T., Schneider-Stock R., Rys J., Niezabitowski A., and Roessner A. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors. J. Cancer Res. Clin. Oncol. 123 (1997) 388-394
57. Hollstein M., Shomer B., Greenblatt M., Soussi T., Hovig E., Montesano R., and Harris C.C. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res. 24 (1996) 141-146
58. Hainaut P., and Pfeifer G.P. Patterns of p53 G→T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis 22 (2001) 367-374
59. Xu J., Zheng S.L., Turner A., Isaacs S.D., Wiley K.E., Hawkins G.A., et al. Associations between hOGG1 sequence variants and prostate cancer susceptibility. Cancer Res. 62 (2002) 2253-2257
60. Rybicki B.A., Conti D.V., Moreira A., Cicek M., Casey G., and Witte J.S. DNA repair gene XRCC1 and XPD polymorphisms and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 13 (2004) 23-29
61. van Gils C.H., Bostick R.M., Stern M.C., and Taylor J.A. Differences in base excision repair capacity may modulate the effect of dietary antioxidant intake on prostate cancer risk: an example of polymorphisms in the XRCC1 gene. Cancer Epidemiol. Biomarkers Prev. 11 (2002) 1279-1284
62. Lunn R.M., Langlois R.G., Hsieh L.L., Thompson C.L., and Bell D.A. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin a variant frequency. Cancer Res. 59 (1999) 2557-2561
63. Tang D., Cho S., Rundle A., Chen S., Phillips D., Zhou J., et al. Polymorphisms in the DNA repair enzyme XPD are associated with increased levels of PAH-DNA adducts in a case-control study of breast cancer. Breast Cancer Res. Treat. 75 (2002) 159-166
64. Hu J.J., Hall M.C., Grossman L., Hedayati M., McCullough D.L., Lohman K., and Case L.D. Deficient nucleotide excision repair capacity enhances human prostate cancer risk. Cancer Res. 64 (2004) 1197-1201
65. Fan R., Kumaravel T.S., Jalali F., Marrano P., Squire J.A., and Bristow R.G. Defective DNA strand break repair after DNA damage in prostate cancer cells: implications for genetic instability and prostate cancer progression. Cancer Res. 64 (2004) 8526-8533
66. Kooiman G.G., Martin F.L., Williams J.A., Grover P.L., Phillips D.H., and Muir G.H. The influence of dietary and environmental factors on prostate cancer risk. Prostate Cancer Prostatic Dis. 3 (2000) 256-258
67. Poirier M.C. Chemical-induced DNA damage and human cancer risk. Nat. Rev. Cancer 4 (2004) 630-637
68. Alexandrov K., Margarita R., Geneste O., Castegnaro M., Camus A.M., Petruzzelli S., et al. An inproved fluorometric assay for dosimetry of benzo(a)pyrene diol-epoxide-DNA adducts in smokers' lung: comparisons with total bulky adducts and aryl hydrocarbon hydroxylase activity. Cancer Res. 52 (1992) 6248-6253
69. 32P-adduct assay: comparative recoveries of structurally diverse DNA adducts in the various enhancement procedures. Carcinogenesis 9 (1988) 1687-1693
70. Santella R. Immunological methods for detection of carcinogen-DNA damage in humans. Cancer Epidemiol. Biomarkers Prev. 8 (1999) 733-739
71. Rundle A., Tang D., Hibshoosh H., Estabrook A., Schnabel F., Cao W., et al. The relationship between genetic damage from polycyclic aromatic hydrocarbons in breast tissue and breast cancer. Carcinogenesis 21 (2000) 1281-1289
72. Romano G., Sgambato A., Boninsegna A., Flamini G., Curigliano G., Yang Q., et al. Evaluation of polycyclic aromatic hydrocarbon-DNA adducts in exfoliated oral cells by an immunohistochemical assay. Cancer Epidemiol. Biomarkers Prev. 8 (1999) 91-96
73. Phillips D.H., Farmer P.B., Beland F.A., Nath R.G., Poirier M.C., Reddy M.V., and Turteltaub K.W. Methods of DNA adduct determination and their application to testing compounds for genotoxicity. Environ. Mol. Mutagen. 35 (2000) 222-233
74. Motykiewicz G., Malusecka E., Grzybowska E., Chorazy M., Zhang Y.J., Perera F.P., and Santella R.M. Immunohistochemical quantitation of polycyclic aromatic hydrocarbon-DNA adducts in human lymphocytes. Cancer Res. 55 (1995) 1417-1422
75. Zenzes M.T., Puy L.A., Bielecki R., and Reed T.E. Detection of benzo[a]pyrene diol epoxide-DNA adducts in embryos from smoking couples: evidence for transmission by spermatozoa. Mol. Hum. Reprod. 5 (1999) 125-131
76. Rundle A., Tang D., Hibshoosh H., Schnabel F., Kelly A., Levine R., et al. Molecular epidemiologic studies of polycyclic aromatic hydrocarbon-DNA adducts and breast cancer. Environ. Mol. Mutagen. 39 (2002) 201-207
77. Rybicki B.A., Rundle A., Savera A.T., Sankey S.S., and Tang D. Polycyclic aromatic hydrocarbon-DNA adducts in prostate cancer. Cancer Res. 64 (2004) 8854-8859
78. Martin F.L., Cole K.J., Muir G.H., Kooiman G.G., Williams J.A., Sherwood R.A., et al. Primary cultures of prostate cells and their ability to activate carcinogens. Prostate Cancer Prostatic Dis. 5 (2002) 96-104
79. Ramesh A., Inyang F., and Knuckles M.E. Modulation of adult rat benzo(a)pyrene (BaP) metabolism and DNA adduct formation by neonatal diethylstilbestrol (DES) exposure. Exp. Toxicol. Pathol. 56 (2004) 129-138
80. Feng Y., Jiang W., and Hein D.W. 2-Aminofluorene-DNA adduct levels in tumor-target and nontarget organs of rapid and slow acetylator Syrian hamsters congenic at the NAT2 locus. Toxicol. Appl. Pharmacol. 141 (1996) 248-255
81. Tang D., Phillips D.H., Stampfer M., Mooney L.A., Hsu Y., Cho S., et al. Association between carcinogen-DNA adducts in white blood cells and lung cancer risk in the physicians health study. Cancer Res. 61 (2001) 6708-6712